Medical News Today -
20 Feb 2014 12:00
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostate surgery. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in more than 5,000 patients across 11 clinical studies."This study represents a great advance in the treatment of prostate cancer.
Share this Article